Filanesib (ARRY-520)

Target: Kinesin spindle protein (KSP) | Indication: Multiple myeloma

Introduction / Brief Description

Filanesib is a highly selective, targeted KSP inhibitor with a mechanism of action distinct from currently available myeloma therapies such as immunomodulatory drugs (IMiDs®) and proteasome inhibitors. Across multiple studies, filanesib has demonstrated activity in heavily pretreated multiple myeloma patients, with a consistent safety profile including no drug-induced peripheral neuropathy and limited non-hematologic toxicity. Adverse events are generally limited to transient, non-cumulative and predominantly asymptomatic myelosuppression (decreases in blood counts) when supportive measures are used. Alpha 1-acid glycoprotein (AAG), a plasma protein, is a potential patient selection marker for filanesib. AAG is undergoing further investigation in clinical trials and could represent the first patient selection marker for a myeloma therapy.

Multiple Myeloma

Multiple myeloma is a cancer of the plasma cells in the bone marrow and is the second most common hematologic malignancy in the United States. Additionally, there are more than 70,000 patients with relapsed and refractory multiple myeloma (RRMM) in developed countries. Despite advancements with new treatments, the vast majority of patients progress on these therapies, leaving an unmet need for novel agents which provide benefit in combination with, and following failure of, existing therapies.

Clinical Trials

Trial Data
Trial Title
Program: Filanesib (ARRY-520)
Phase: 1
Status: Active, not recruiting
Disease: Relapsed/refractory multiple myeloma
Sponsor: M.D. Anderson Cancer Center
Trial Information: NCT01372540
Trial Title: ARRY-520 + Carfilzomib for Multiple Myeloma


American Society of Hematology Annual Meeting

Prolonged Survival and Improved Response Rates with ARRY-520 in Relapsed/Refractory Multiple Myeloma (RRMM) Patients with Low Alpha-1 Acid Glycoprotein (AAG) levels: Results from a Phase 2 Study

S. Lonial, M.D. et al.

Open PDF File

American Society of Hematology Annual Meeting

Phase I Study of the Novel Kinesin Spindle Protein Inhibitor Filanesib (ARRY-520) + Carfilzomib (Car) in Patients with Relapsed and/or Refractory Multiple Myeloma

J.J. Shah, MD, et al.

Open PDF File

American Society of Hematology Annual Meeting

A Phase 1 Study of ARRY-520 (Filanesib) with Bortezomib in Relapsed or Refractory Multiple Myeloma

A. Chari, M.D., et al.

Open PDF File

American Society of Hematology Annual Meeting

ARRY-520 Combined with Pomalidomide Displays Enhanced Anti-Tumor Activity in Preclinical Models of Multiple Myeloma

M. J. Humphries, et al.

Open PDF File


To view all publications, click here.